NEW HAVEN, Conn., Dec. 5, 2019 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the
"Company"), a clinical stage biopharmaceutical company with a
portfolio of late-stage product candidates for neurological and
neuropsychiatric diseases, announced today that the U.S. Patent and
Trademark Office ("USPTO") issued U.S. Pat. No. 10,485,791 on
November 26, 2019 relating to
troriluzole.
Biohaven's patent is directed to the composition of matter of
troriluzole, a novel prodrug of a glutamate modulator, as well as
other compounds, pharmaceutical compositions and methods of
treating diseases including, for example, neurological disorders
such as Alzheimer's disease, generalized anxiety disorder, social
anxiety disorder, and depression. The U.S. patent is not
expected to expire before February 26,
2036, not including a possible patent term restoration of up
to five years as provided under the Drug Price Competition and
Patent Restoration Act (35 U.S.C. §156).
Vlad Coric, M.D., CEO of Biohaven
commented, "We are particularly excited about the grant of this
composition of matter patent in anticipation of upcoming results
from multiple troriluzole Phase 2/3 clinical trials. The USPTO's
issuance of this patent enhances the strength of our intellectual
property protection around glutamate modulating agents and
troriluzole. This patent further supports our ongoing R&D
efforts in treating neurologic and neuropsychiatric disorders,
including Alzheimer's disease. Given the devastating impact of
neurologic and neuropsychiatric disease on patients, their families
and the healthcare system, we need to urgently assess novel
treatment interventions targeting the underlying pathophysiology of
this illness."
About Troriluzole
Troriluzole is a third-generation prodrug and new chemical
entity that modulates glutamate, the most abundant excitatory
neurotransmitter in the human body. The primary mode of action of
troriluzole is normalizing synaptic levels of glutamate.
Troriluzole increases glutamate uptake from the synapse, by
augmenting the expression and function of excitatory amino acid
transporters located on glial cells that play a key role in
clearing glutamate from the synapse. More information about
troriluzole can be found at the
Company's
website: https://www.biohavenpharma.com/science-pipeline/glutamate/troriluzole
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
combined internal development and research with intellectual
property licensed from companies and institutions including
Bristol-Myers Squibb Company, AstraZeneca AB, Yale University,
Catalent, Rutgers, and ALS Biopharma LLC. Currently,
Biohaven's lead development programs include multiple compounds
across its CGRP receptor antagonist, glutamate modulation, and
myeloperoxidase inhibitor platforms. Biohaven's common shares are
listed on the New York Stock Exchange and traded under the ticker
symbol BHVN. More information about Biohaven is available
at www.biohavenpharma.com.
Forward-Looking Statements
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of the Company's management. All
statements, other than statements of historical facts, included in
this press release, including any expected patent expiration dates,
relationship of the patent to any of the Company's programs
including generalized anxiety disorder, social anxiety disorder,
depression or Alzheimer's disease are forward-looking statements.
The use of certain words, including the "believe" and "will" and
similar expressions are intended to identify forward-looking
statements. The Company may not actually achieve the plans and
objectives disclosed in the forward-looking statements and you
should not place undue reliance on the Company's forward-looking
statements. Various important factors could cause actual results or
events to differ materially from those that may be expressed or
implied by our forward-looking statements, including uncertainties
relating to the future clinical success of troriluzole. Additional
important factors to be considered in connection with
forward-looking statements are described in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2018, as updated by the Company's
subsequent Quarterly Reports on Form 10-Q. The forward-looking
statements are made as of this date and the Company does not
undertake any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
Biohaven Contact
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-issuance-of-composition-of-matter-patent-on-troriluzole-by-the-us-patent-and-trademark-office-300970399.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.